Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study

Fig. 1

Change in CDAI after introducing IL-6 receptor inhibitor. The diagram is based on adjusted data. Mean ± standard error is shown. Abbreviations: CDAI, clinical disease activity index; IV, intravenous; SAR, sarilumab; SC, subcutaneous; TCZ, tocilizumab

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us